 TORONTO, ON ACCESSWIRE April 22, 2021 Intellipharmaceutics International Inc. OTCQB:IPCIF and TSX:IPCI Intellipharmaceutics or the Company, a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, is pleased to announce the completion of a non-brokered private placement the Private Placement of 9,414,560 common shares of the Company the Common Shares at a price of CAD0.41 per Common Share for total gross proceeds of CAD3,859,969.60. The proceeds of the Private Placement are expected to be used to maintain the Companys existing operations and for general working capital purposes and to fund research and development activities. 